Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases
Frontiers in Oncology · 04.06.2026 · 16
DOI: 10.3389/fonc.2026.1825642 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 04.06.2026. Verfasst von Hua Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Beijing Fengtai You'anmen Hospital, Beijing, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The development of a ROS1 fusion as a bypass signaling pathway mediating resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) is rare, with only sporadic cases reported in the literature. Consequently, no consensus exists on the optimal treatment sequencing for such patients. We report the case of a 61-year-old woman diagnosed with stage IV lung adenocarcinoma with brain metastasis harboring an EGFR exon 19 deletion (p.E746_A750del), who acquired resistance to osimertinib through a ROS1 fusion bypass pathway. The patient achieved a survival of over 6.5 years from initial diagnosis through ongoing adjustments to targeted therapy, including sequential treatment with crizotinib, entrectinib, and lorlatinib. Although all three agents target ROS1, they exhibited distinct side effect profiles in this patient. Notably, we observed an interesting phenomenon with both crizotinib and entrectinib: while initial treatment led to intolerable adverse reactions requiring discontinuation, subsequent reintroduction of the same agent was well-tolerated. This case report aims to provide potential treatment strategies for patients with similar complex co-mutations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Beijing Fengtai You'anmen Hospital, Beijing, China.
Zitieren
APA
Yang, H., Da, Y., Shen, G., Sun, Q. Y., Yao, Z. Y., & Zhou, Y. J. (2026). Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1825642
Vancouver
Yang H, Da Y, Shen G, Sun QY, Yao ZY, Zhou YJ. Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1825642
BibTeX
@article{Yang2026,
author = {Yang, Hua and Da, Yong and Shen, Ge and Sun, Qi-Yun and Yao, Zhi-Yu and Zhou, Ya-Jing},
title = {Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1825642}
}
EUVIMED